search
Back to results

FST-201 In The Treatment of Acute Otitis Externa

Primary Purpose

Acute Otitis Externa

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
FST-201 (dexamethasone 0.1%) Otic Suspension
ciprofloxacin 0.3%, dexamethasone 0.1%
Sponsored by
Shire
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Otitis Externa

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have a clinical diagnosis of AOE in one or both ears, defined as a clinical score of at least 1 for edema (0-3 scale), 2 for overall inflammation (0-3 scale) and 1 for tenderness (absent=0, present=1).
  • Be at least 18 years of age at Visit 1 (Day 1, Screening/Baseline) of either sex and any race.
  • Provide written informed consent or parental assent.
  • Be willing and able to follow all instructions and attend all study visits

Exclusion Criteria:

All subjects must not:

  • Have known sensitivity to any component of the study medications
  • Have a current infection requiring systemic antimicrobial treatment
  • Have used topical or systemic pain meds on the same day as Screening/Baseline Visit 1 and for the duration of the study.
  • Take any systemic (within 30 days) or otic corticosteroids (within 1 days) prior to Screening/Baseline Visit 1
  • Current use of topical or systemic non-steroidal or other anti-inflammatory drugs.
  • Use any topical otic treatment with alcohol, vinegar, hydrogen peroxide or other astringent medication during the course of the study or on the same day as Screening/Baseline Visit 1
  • Have taken any antibiotics within 3 days prior to Visit 1
  • Have signs and symptoms of AOE for > 4 weeks at Screening/Baseline Visit 1
  • Have a non-intact or perforated tympanic membrane in the enrolled ear
  • Have a clinical diagnosis of chronic suppurative otitis media, acute otitis media or acute otorrhea in patients with tympanostomy tubes
  • Have a clinical diagnosis of malignant otitis externa
  • Have overt fungal AOE
  • Have a viral infection of the pinna or tympanic membrane (i.e herpes zoster)
  • Have congenital abnormalities of the external auditory canal in the enrolled ear(s)
  • Have obstructive bony exostoses in the enrolled ear(s)
  • Have mastoid or other suppurative, non-infectious ear disorders (e.g, cholesteatoma)
  • Have malignant tumors of the external auditory canal
  • Have a history of otologic surgery. Surgery performed more than 1 year prior to Screening/Baseline Visit 1and limited to the tympanic membrane is allowed
  • Have seborrheic dermatitis of the external auditory canal
  • Have a current or prior history of immunosuppressive disorders
  • Have acute or chronic renal insufficiency, hepatitis or diabetes mellitus
  • Be pregnant, nursing or planning a pregnancy.

Sites / Locations

  • ENT Associates of South Florida
  • Austin Ear, Nose, and Throat Clinic
  • San Antonio Ear, Nose, and Throat Research
  • San Antonio Ear, Nose, and Throat Research
  • Ear Institute of Texas

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

FST-201 (dexamethasone 0.1%) Otic Suspension

ciprofloxacin 0.3%, dexamethasone 0.1%

Arm Description

Outcomes

Primary Outcome Measures

Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.

Secondary Outcome Measures

Microbiological resolution defined as elimination of pre-treatment pathogenic bacteria.

Full Information

First Posted
July 23, 2009
Last Updated
May 24, 2021
Sponsor
Shire
search

1. Study Identification

Unique Protocol Identification Number
NCT00945802
Brief Title
FST-201 In The Treatment of Acute Otitis Externa
Official Title
A Multi-Center, Randomized, Double-Masked Clinical Study Evaluating the Efficacy Of FST-201 (Dexamethasone 0.1%) Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex (Ciprofloxacin 0.3%, Dexamethasone 0.1%) Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Terminated
Study Start Date
July 31, 2009 (Actual)
Primary Completion Date
July 31, 2010 (Actual)
Study Completion Date
July 31, 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shire

4. Oversight

5. Study Description

Brief Summary
The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Otitis Externa

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FST-201 (dexamethasone 0.1%) Otic Suspension
Arm Type
Experimental
Arm Title
ciprofloxacin 0.3%, dexamethasone 0.1%
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
FST-201 (dexamethasone 0.1%) Otic Suspension
Intervention Description
Instill four drops two times a day
Intervention Type
Drug
Intervention Name(s)
ciprofloxacin 0.3%, dexamethasone 0.1%
Other Intervention Name(s)
Ciprodex
Intervention Description
Instill four drops two times a day
Primary Outcome Measure Information:
Title
Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Microbiological resolution defined as elimination of pre-treatment pathogenic bacteria.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have a clinical diagnosis of AOE in one or both ears, defined as a clinical score of at least 1 for edema (0-3 scale), 2 for overall inflammation (0-3 scale) and 1 for tenderness (absent=0, present=1). Be at least 18 years of age at Visit 1 (Day 1, Screening/Baseline) of either sex and any race. Provide written informed consent or parental assent. Be willing and able to follow all instructions and attend all study visits Exclusion Criteria: All subjects must not: Have known sensitivity to any component of the study medications Have a current infection requiring systemic antimicrobial treatment Have used topical or systemic pain meds on the same day as Screening/Baseline Visit 1 and for the duration of the study. Take any systemic (within 30 days) or otic corticosteroids (within 1 days) prior to Screening/Baseline Visit 1 Current use of topical or systemic non-steroidal or other anti-inflammatory drugs. Use any topical otic treatment with alcohol, vinegar, hydrogen peroxide or other astringent medication during the course of the study or on the same day as Screening/Baseline Visit 1 Have taken any antibiotics within 3 days prior to Visit 1 Have signs and symptoms of AOE for > 4 weeks at Screening/Baseline Visit 1 Have a non-intact or perforated tympanic membrane in the enrolled ear Have a clinical diagnosis of chronic suppurative otitis media, acute otitis media or acute otorrhea in patients with tympanostomy tubes Have a clinical diagnosis of malignant otitis externa Have overt fungal AOE Have a viral infection of the pinna or tympanic membrane (i.e herpes zoster) Have congenital abnormalities of the external auditory canal in the enrolled ear(s) Have obstructive bony exostoses in the enrolled ear(s) Have mastoid or other suppurative, non-infectious ear disorders (e.g, cholesteatoma) Have malignant tumors of the external auditory canal Have a history of otologic surgery. Surgery performed more than 1 year prior to Screening/Baseline Visit 1and limited to the tympanic membrane is allowed Have seborrheic dermatitis of the external auditory canal Have a current or prior history of immunosuppressive disorders Have acute or chronic renal insufficiency, hepatitis or diabetes mellitus Be pregnant, nursing or planning a pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Study Director
Organizational Affiliation
Takeda
Official's Role
Study Director
Facility Information:
Facility Name
ENT Associates of South Florida
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33426
Country
United States
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34239
Country
United States
Facility Name
Austin Ear, Nose, and Throat Clinic
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
San Antonio Ear, Nose, and Throat Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78215
Country
United States
Facility Name
San Antonio Ear, Nose, and Throat Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Ear Institute of Texas
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States

12. IPD Sharing Statement

Learn more about this trial

FST-201 In The Treatment of Acute Otitis Externa

We'll reach out to this number within 24 hrs